0001439222-23-000047.txt : 20230303
0001439222-23-000047.hdr.sgml : 20230303
20230303160537
ACCESSION NUMBER: 0001439222-23-000047
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230301
FILED AS OF DATE: 20230303
DATE AS OF CHANGE: 20230303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gheuens Sarah
CENTRAL INDEX KEY: 0001881190
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36014
FILM NUMBER: 23703805
MAIL ADDRESS:
STREET 1: C/O AGIOS PHARMACEUTICALS, INC.
STREET 2: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001439222
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-8600
MAIL ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20080703
4
1
wf-form4_167787751050589.xml
FORM 4
X0306
4
2023-03-01
0
0001439222
AGIOS PHARMACEUTICALS, INC.
AGIO
0001881190
Gheuens Sarah
88 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common stock
2023-03-01
4
M
0
3833
0
A
21250
D
Common stock
2023-03-03
4
F
0
1134
25.02
D
20116
D
Restricted stock units
2023-03-01
4
A
0
12000
0
A
Common stock
12000.0
12000
D
Stock options (right to buy)
25.01
2023-03-01
4
A
0
44000
0
A
2033-03-01
Common stock
44000.0
44000
D
Restricted stock units
2023-03-01
4
M
0
3833
0
D
Common stock
3833.0
7667
D
Includes 408 shares purchased through the Company's employee stock purchase plan.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.
The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.
/s/ William Cook, as attorney-in-fact for Sarah Gheuens
2023-03-03